# Essai Clinique

Généré le 18 mars 2025 à partir de

| | |
|---|---|
| Titre | Meilleure préservation d'organe : Proposition d'étude multicentrique (Morpheus) comparant la curiethérapie à haut débit de dose à la radiothérapie externe guidée par l'image – Une étude de phase III à répartition aléatoire |
| Protocole ID | Morpheus study (no surgery) |
| ClinicalTrials.gov ID | NCT03051464 |
| Type(s) de cancer | Colorectal |
| Type étude | Clinique |
| Institution | CISSS DE L'OUTAOUAIS<br>HOPITAL DE GATINEAU<br>909 Boulevard La Vérendrye, Gatineau, QC, J8P 7H2 |
| Ville | |
| Investigateur principal | Dr Robert Archambault |
| Coordonnateur | Céline Roy<br>819-966-6100 poste 3669 |
| Statut | Actif en recrutement |
| But étude | A pilot study of 40 patients. Patients with a clinical T2-3 N0-1 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy compared to arm B: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions). |
| Critères d'éligibilité | • Rectal cancer patients, clinically staged as T2-T3 by MRI or endoscopic/trans-rectal ultrasound<br>• Rectal cancer staged as N0-N1 by MRI or EUS/TRUS<br>• No metastatic lesion<br>• Rectal tumor occupying less than half of the circumference<br>• Tumor less than 5 cm on its largest dimension<br>• Tumor located at less than 10 cm from the anal verge<br>• Tumor penetration less than 5 mm in the mesorectal fat<br>• Tumor accessible for brachytherapy<br>• Lumen accessible for colonoscopy<br>• Patient should be a suitable candidate for brachytherapy and chemotherapy<br>• Older than 18 years of age<br>• Adequate birth control measures in women of childbearing potential<br>• Written informed consent |
| Critères d'exclusion | • Patients with previous pelvic radiation<br>• Evidence of distant metastasis<br>• Extension of malignant disease to the anal canal<br>• Tumors staged as T4<br>• Tumors larger than 5 cm in length |